Amedisys (AMED)
(Delayed Data from NSDQ)
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.
Amedisys (AMED) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amedisys (AMED) Q1 Earnings Top Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 16.28% and 0.58%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable
by Zacks Equity Research
For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.
Here's Why You Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.
Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips
by Zacks Equity Research
Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.
Amedisys (AMED) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 12.62% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Amedisys (AMED) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys (AMED) Faces Macro Challenges, Margin Pressure
by Zacks Equity Research
The Contessa Health acquisition seems to be strategically aligned with Amedisys' (AMED) business.
Are Options Traders Betting on a Big Move in Amedisys (AMED) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.
Amedisys (AMED) Q3 Earnings Miss Estimates, Guidance Cut
by Zacks Equity Research
Within Amedisys (AMED) Home Health and Hospice, the reinstatement of sequestration reduces growth in Q3.
Amedisys (AMED) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -7.26% and 3.41%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Amedisys (AMED) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.
3 Stocks to Watch From the Pandemic-Hit Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. AMED, ADUS and HNGR are well poised to gain from the prospects.
Here's Why Investors Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.
Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.
Amedisys (AMED) Q2 Earnings Beat Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 19.51% and 4.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Encompass Health (EHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Amedisys (AMED) Q2 Earnings Expected to Decline
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care
by Zacks Equity Research
Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.
Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range
by Zacks Equity Research
Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.
Are Options Traders Betting on a Big Move in Amedisys (AMED) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.
Amedisys (AMED) Down 11% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Investors are optimistic about the robust performances of Amedisys' (AMED) Home Health and Hospice segments.